This morning, the United Kingdom’s National Health Service (NHS) announced that it has completed negotiations over using the best-value adalimumab product, and it has arrived at a plan whereby it will save £300 million (approximately $386 million) of its current £400 million-per-year (approximately $514 million) spending on adalimumab.
This morning, the United Kingdom’s National Health Service (NHS) announced that it has completed negotiations over using the best-value adalimumab product, and it has arrived at a plan whereby it will save £300 million (approximately $386 million) of its current £400 million-per-year (approximately $514 million) spending on adalimumab.
These substantial savings, said the NHS, will allow the health system to pay for an additional 11,700 community nurses, or 19,800 more treatments for patients with breast cancer. The deal also puts the NHS on track to deliver on its efforts to save.
In announcing the deal that affects the more than 46,000 UK patients currently treated with the reference adalimumab (Humira), Simon Stevens, NHS England’s chief executive, said, “As part of the NHS’s Long Term Plan we are ensuring every penny of extra investment is wisely spent. Harnessing the power of competition between drug companies, NHS England has now freed up hundreds of millions of pounds of savings to reinvest in patient care. By working with patients and frontline clinicians we’ve now successfully negotiated the biggest ever set of savings on what was the NHS’ most costly drug.”
The NHS revealed that it had taken bids from biosimilar developers Amgen, Samsung Bioepis, Mylan, and Sandoz, as well as from AbbVie, maker of the reference adalimumab, Humira. While the NHS did not disclose how each of the developers fared in the tendering process, the NHS, in its October 2018 final briefing on the adalimumab tender process, said that it planned award lots to 4 biosimilar products, and the size of each lot would depend upon the strength of the offers made. The strategy meant that no supplier of adalimumab would be awarded the full market, but that each company would have an incentive to offer the most competitive price.
Now that the NHS has awarded its tenders, the work of implementing the transition to biosimilars begins. Prior to the advent of biosimilar adalimumab, the NHS released its commissioning framework for biologics, which seeks to ensure that at least 90% of new patients be prescribed the best-value adalimumab, and that 80% of existing patients be switched to the best-value adalimumab, within a year of a biosimilar’s launch. The NHS Specialist Pharmacy Service also released a suite of resources for clinicians to use with patients in discussions about switching from Humira to a biosimilar. These resources include a Frequently Asked Questions document, as well as a template of patient letter with information about what the switch might mean for them.
Switching patients to biosimilars has already led to significant cost savings for the NHS: infliximab biosimilars delivered £99.4 million in savings, etanercept biosimilars delivered £60.3 million, and rituximab biosimilars delivered £50.4 million, for a cumulative savings equivalent to approximately $275 million in US currency during the 2017 to 2018 fiscal year.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.